Aspire Biopharma settles lender default claims, extends note maturities by 75 days

Aspire Biopharma Holdings, Inc.

Lenders withdrew April 1 and April 9 default/acceleration notices; defaults deemed cured with no admission of fault.
Maturities extended: Dec 13 note to Aug 15, 2025; Sep/Oct 2024 notes to Sep 10, 2025.
Company to issue 625,000 shares to Blackstone and file S-1 registration by May 13, 2025.
Lock-ups removed for Cobra, Blackstone, Thor; new leak-out restrictions based on trading volume through Aug 20, 2025.
Lenders waived additional interest/penalties; company to pay up to $60,000 in deal costs added to principal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.